Gilead, J&J Sue Laurus Labs to Block Copy of HIV Drug Complera

Laurus Labs Ltd.’s proposed generic version of Complera infringes three patents for the HIV treatment, two a Johnson & Johnson unit licenses to Gilead Sciences Inc. and a third they own jointly, a federal lawsuit said.

J&J’s Janssen Sciences Ireland Unlimited Co. subsidiary and Gilead allege Laurus’ copies infringe their co-owned US Patent No. 10,857,102 and Janssen’s US Patent Nos. 8,618,291 and 8,101,752, which are exclusively licensed to Gilead, according to a complaint filed Monday in the US District Court for the District of New Jersey. Laurus’ regulatory filings have indicated “they only intend on respecting patents that expire ...